The hashimoto's thyroiditis therapeutics market is projected to grow from USD 8.8 billion in 2025 to USD 15.4 billion by 2035, at a CAGR of 5.8%. Oral Powders will dominate with a 33.8% market share, while intravenous will lead the route of administration segment with a 58.4% share.